TLE4

Across TCGA pan-cancer cohorts, TLE4 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TLE4 data layer compared with 24 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TLE4 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated TLE4 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, UCEC, and LUAD are the cancer types where TLE4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	III,IV	0.977	0.376	<.001	14	view →
UCEC	DFS	Tertile	II,III,IV	0.409	1.000	.018	14	view →
LUAD	DFS	Quartile	All	0.761	0.408	.005	12	view →
GBM	OS	Median	All	0.601	0.449	.024	3	view →
HNSC	DFS	Quartile	II,III,IV	1.000	0.864	.028	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TLE4–PDAC (OS)

Open the PDAC breakdown →